← Back to Search

Vaccine Education for Rheumatic Diseases

N/A

Recruiting

Led By Rosalind Ramsey-Goldman, MD, DrPH

Research Sponsored by Northwestern University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 months

Awards & highlights

No Placebo-Only Group

Summary

This trial tests whether training community leaders can help more Black adults with rheumatic conditions get the COVID-19 vaccine and boosters.

Who is the study for?

This trial is for Black individuals aged 18-85 with rheumatic diseases who want to help their community understand COVID-19 vaccines better. They must speak English, identify as Black/African American/African descent, and have a social network. Members of this network should be adults not fully vaccinated against COVID.

What is being tested?

The study tests two types of training given to Popular Opinion Leaders (POLs) in the Black community on the benefits of COVID-19 vaccines and boosters. The goal is to see if these trainings can increase vaccine uptake and reduce hesitancy within their networks.

What are the potential side effects?

Since this trial focuses on educational interventions rather than medical treatments, there are no direct side effects from medications or vaccines being studied here.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Receipt of >1 COVID-19 vaccine or booster dose

Secondary study objectives

Change in COVID-19 vaccine hesitancy

Structure and composition of the Popular Opinion Leader outreach networks.

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: COVID-19 vaccine and booster training with extra undisclosed componentExperimental Treatment1 Intervention

Group training involving COVID-19 vaccine and booster information, including background, development, and myths. Contains extra training component that is undisclosed until the end of the study so as not to introduce bias.

Group II: COVID-19 vaccine and booster trainingActive Control1 Intervention

Group training involving COVID-19 vaccine and booster information, including background, development, and myths.

Do I qualify?Apply below to find out